Chagas disease (CD) is a well-defined risk factor for stroke. But the prognostic significance of stroke prevalence in left ventricular ejection fraction (LVEF) reduced compared to preserved LVEF in patients with heart failure and with CD, is still poorly known.
[…]
Occurrence of Stroke and Reduced Ejection Fraction in Patients with
Chagas Disease
SampaioES, OliveiraMMC, ArasR. Occurrence of Stroke and Reduced Ejection Fraction in Patients with
Chagas Disease. Arq. Bras.
Cardiol. 2018;110(3):297.
Sampaio,Elieusa e Silva; Oliveira,Márcia Maria Carneiro; Aras,Roque. Occurrence of Stroke and Reduced Ejection Fraction in Patients with
Chagas Disease. Arq. Bras.
Cardiol., v. 110, n. 3, p. 297-297, Mar. 2018.
Sampaio,E.S., Oliveira,M.M.C., & Aras,R. (2018). Occurrence of Stroke and Reduced Ejection Fraction in Patients with
Chagas Disease. Arq. Bras.
Cardiol.,110(3), 297-297.
Sampaio,Elieusa e Silva and Oliveira,Márcia Maria Carneiro and Aras,Roque. Occurrence of Stroke and Reduced Ejection Fraction in Patients with
Chagas Disease. Arq. Bras.
Cardiol. [online]. 2018, vol. 110, n. 3, [cited 2025-09-07], pp.297-297. Available from: <https://abccardiol.org/en/article/occurrence-of-stroke-and-reduced-ejection-fraction-in-patients-withchagas-disease/>. ISSN 0066-782X.
Figure 1
Dyslipidemia as a central element in atherosclerotic cardiovascular disease. ASCVD: atherosclerotic cardiovascular disease; LDL-C: low-density lipoprotein cholesterol. Limitations of statin-based therapy (non-exhaustive) include suboptimal LDL-C goal attainment, statin-associated adverse effects that may affect adherence, and potential drug interactions. Residual risk reflects the involvement of multiple underlying pathways.